RECRUITING

Alveolar Macrophage Programming Following Endotoxin Exposure

Conditions

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The histologic hallmarks of lung inflammation include accumulation of inflammatory cells in the airspaces and interstitium, injury to alveolar epithelial and endothelial cells, loss of epithelial-capillary integrity and accumulation of edema fluid in the interstitium and airspaces. Accordingly, for alveolar repair to occur inflammation must be halted, debris and inflammatory cells removed, injured tissue cells replaced, and capillary barrier function re-established. Macrophages are key players in all of these. Here the investigators hypothesize that resident alveolar macrophages and recruited macrophages serve completely different functions, acting independently (i.e. division of labor) yet cooperatively (synergism).

Official Title

Alveolar Macrophage Programming Following Endotoxin Exposure

Quick Facts

Study Start:2019-03-18
Study Completion:2032-07
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT03859050

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 50 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Written, informed consent
  2. 2. Age 18-50
  1. 1. Current or recent illness (past 2 weeks)
  2. 2. Presence or prior history of cardiac, pulmonary or systemic disease
  3. 3. Bleeding disorder, use of systemic anticoagulants or antiplatelet therapy
  4. 4. American Society of Anesthesiology (ASA) class 2 or greater
  5. 5. Immunocompromised state (HIV, immunoglobulin deficiency, systemic immunosuppressants)
  6. 6. Use of any inhaled substance, including tobacco, marijuana, e-cigarrettes, cocaine, methamphetamines, or toxic vapors in the past 3 months or greater than 10 pack-year smoking history
  7. 7. Alcohol use disorder or greater than 7 drinks/week for women or greater than 14 drinks/week for men in the past 3 months
  8. 8. Allergy or prior adverse reaction to lidocaine, midazolam or fentanyl
  9. 9. Abnormal spirometry or electrocardiogram at time of screening
  10. 10. Pregnant (based on urine pregnancy test) or breast feeding

Contacts and Locations

Study Contact

Kara Mould
CONTACT
303-398-1787
mouldk@njhealth.org

Study Locations (Sites)

National Jewish Health
Denver, Colorado, 80206
United States

Collaborators and Investigators

Sponsor: National Jewish Health

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2019-03-18
Study Completion Date2032-07

Study Record Updates

Study Start Date2019-03-18
Study Completion Date2032-07

Terms related to this study

Additional Relevant MeSH Terms

  • ARDS, Human